Achiko AG (OTCQB:ACHKF) CEO Steven Goh tells Proactive the group has recently completed validated testing of its coronavirus rapid test AptameX in Indonesia, the data to be used to support its CE mark application for the test approval in Europe.
Goh says Achiko's DNA aptamer diagnostic test has 'dramatically more accurate results' than any other rapid test, which he says is comparable to the sensitivity of a PCR test.